Cue Biopharma, Inc. (NASDAQ:CUE) Shares Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP increased its stake in shares of Cue Biopharma, Inc. (NASDAQ:CUE) by 5.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 291,663 shares of the company’s stock after acquiring an additional 14,104 shares during the period. GSA Capital Partners LLP owned about 0.60% of Cue Biopharma worth $221,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of CUE. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Cue Biopharma in the 2nd quarter valued at about $66,000. Good Life Advisors LLC boosted its position in shares of Cue Biopharma by 23.1% during the 3rd quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock worth $303,000 after purchasing an additional 75,000 shares during the period. Sigma Planning Corp raised its position in Cue Biopharma by 50.9% in the third quarter. Sigma Planning Corp now owns 401,325 shares of the company’s stock valued at $304,000 after purchasing an additional 135,295 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Cue Biopharma by 7.1% during the 1st quarter. Vanguard Group Inc. now owns 2,283,362 shares of the company’s stock worth $4,316,000 after acquiring an additional 150,457 shares in the last quarter. 35.04% of the stock is owned by institutional investors and hedge funds.

Cue Biopharma Trading Down 1.0 %

NASDAQ:CUE opened at $1.02 on Monday. The stock has a market cap of $64.62 million, a P/E ratio of -1.13 and a beta of 1.80. Cue Biopharma, Inc. has a 1 year low of $0.45 and a 1 year high of $3.25. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.22 and a current ratio of 2.22. The stock has a 50-day simple moving average of $1.19 and a 200-day simple moving average of $1.13.

Wall Street Analysts Forecast Growth

Separately, Stifel Nicolaus decreased their price target on shares of Cue Biopharma from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $5.00.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.